Association of serum autoantibodies with pregnancy outcome of patients undergoing first IVF/ICSI treatment: A prospective cohort study. (August 2017) - Chen, Xian
Highlights: The IgG of aCL might negatively associate with pregnancy outcome of IVF/ICSI. The IgM of aCL might significantly increase the risk of miscarriage. The IgG of aβ2 GPI might markedly decrease the rate of implantation. Low-dose aspirin could improve the IVF/ICSI outcome. Abstract: The relevance of antiphospholipid (aPL), antinuclear (ANA) or antithyroid (ATA) antibodies in women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) are controversial. The present study aims to investigate which autoantibodies are associated with the pregnancy outcome of patients undergoing first IVF/ICSI treatment. A total of 3763 IVF/ICSI patients were recruited from January to December 2015. Forty-five patients positive for aPL presenting adverse outcomes in their first cycle received low-dose aspirin treatment before the second transfer. Logistic regression analyses were performed to assess any association between autoantibodies and IVF/ICSI outcomes. The aCL-IgG was significantly associated with live birth rate (OR 0.58, 95% CI 0.36–0.96, p < 0.05) and miscarriage rate (OR 2.04, 95% CI 1.23–3.40, p < 0.01). The aCL-IgM was associated with miscarriage rate (OR 2.14, 95% CI 1.29–3.54, p < 0.01). The aβ2 GPI-IgG was associated with implantation rate and clinical pregnancy rate (OR 0.61, 95% CI 0.24–0.96, p < 0.05; OR 0.40, 95% CI 0.13–0.87, p < 0.05, respectively). After the low-dose aspirin treatment, the live birth rate (37.0% vs. 19.1%, p < 0.05) increased significantly in patients with positive for aPL. In contrary, the aβ2 GPI-IgM, ANA, anti-thyroglobulin (aTG) and anti-thyroperoxidase (aTPO) antibodies had no association with IVF/ICSI outcome. It is suggested that the presence of aCL-IgG, aCL-IgM and aβ2 GPI-IgG might exert a detrimental effect on IVF/ICSI outcomes. Low-dose aspirin treatment could be useful for patients positive for these antibodies. Therefore, it is suggested that these antibodies should be assessed prior to IVF/ICSI treatment.